Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

Figure 3

Effect of NVP-BEZ235 alone or combined with Sorafenib on renal cancer apoptosis. A, 786-0 (left panel) or Caki-1 cells (right panel) were treated for 24 hours with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Cells were harvested and apoptosis was measured by quantifying DNA fragmentation. Columns, mean enrichment factor at 405 nm of three independent experiments; bars, SD. B, 786-0 and Caki-1 cells were treated as in A for 48 hours and processed for cell cycle analysis. One of three similar experiments is shown. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets.

Back to article page

Molecular Cancer

ISSN: 1476-4598